Le produit a bien été ajouté au panier.

discount label
H-SLFRAVITK^-OH
Vue en 3D

Biosynth logo

H-SLFRAVITK^-OH

Ref. 3D-PP42137

Taille indéfinieÀ demander
Livraison estimée en/au États-Unis, le mardi 5 novembre 2024

Informations sur le produit

Nom :
H-SLFRAVITK^-OH
Description :

Peptide H-SLFRAVITK^-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-SLFRAVITK^-OH include the following: Identification of a MAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-B* 5701 tumors V Corbiere , H Nicolay , V Russo, V Stroobant - Tissue , 2004 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1111/j.0001-2815.2004.00203.x Degenerate and promiscuous recognition by CTL of peptides presented by the MHC class I A3-like superfamily: implications for vaccine development. SC Threlkeld, PA Wentworth, SA Kalams - (Baltimore, Md.: 1950 , 1997 - journals.aai.orghttps://journals.aai.org/jimmunol/article-abstract/159/4/1648/42488 A NOVel ELISPOT assay to quantify HLA-specific B cells in HLA-immunized individuals S Heidt , DL Roelen, YJH de Vaal, MGD Kester - American journal of , 2012 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1600613522274760 A reversible functional defect of CD8+ T lymphocytes involving loss of tetramer labeling N Demotte, D Colau, S Ottaviani - European journal of , 2002 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/1521-4141(200206)32:6%3C1688::AID-IMMU1688%3E3.0.CO;2-9 Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation M Widenmeyer, Y Shebzukhov - Journal of Cancer, 2011 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.25601 Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies KA Chianese-Bullock, ST Lewis, NE Sherman - Vaccine, 2009 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X09000553 MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA KA Chianese-Bullock, J Pressley, C Garbee - The Journal of , 2005 - journals.aai.orghttps://journals.aai.org/jimmunol/article/174/5/3080/36807 First clinical experience: osteosarcoma patient vaccinated with monocyte-derived dendritic cells, pulsed with tumor specific MAGE-peptides JFM Jacobs, GJ Adema, IJM de Vries - PDF hosted at the , 2009 - core.ac.ukhttps://core.ac.uk/download/pdf/16158885.pdf#page=96 Peptide vaccination in montanide adjuvant induces and GM-CSF increases CXCR3 and cutaneous lymphocyte antigen expression by tumor antigen-specific CD8 T E Clancy-Thompson, LK King, LD Nunnley - Cancer immunology , 2013 - AACRhttps://aacrjournals.org/cancerimmunolres/article-abstract/1/5/332/466869 Stability of Multi-Peptide Vaccines in Conditions Enabling Accessibility in Limited Resource Settings E Ashkani, B McKenna, J Bryant, D Silva, N Sherman - 2024 - researchsquare.comhttps://www.researchsquare.com/article/rs-4345166/latest Effect of GM-CSF on circulating CD8+ and CD4+ T cell responses to a multipeptide melanoma vaccine: Outcome of a multicenter randomized trial CL Slingluff Jr , GR Petroni , WC Olson - cancer research: an , 2009 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778314/ Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a CL Slingluff Jr , GR Petroni , WC Olson, ME Smolkin - Clinical Cancer , 2009 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/15/22/7036/74944 Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma C Capasso, M Hirvinen, M Garofalo , D Romaniuk - , 2016 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/2162402X.2015.1105429

Avis:
Nos produits sont destinés uniquement à un usage en laboratoire. Pour tout autre usage, veuillez nous contacter.
Marque:
Biosynth
Stockage à long terme :
Notes :

Propriétés chimiques

MDL:
Point de fusion :
Point d'ébullition :
Point d'éclair :
Densité :
Concentration :
EINECS :
Merck :
Code SH :

Informations sur les risques

Numéro ONU :
EQ:
Classe :
Phrases R :
Phrases S :
Transport aérien interdit :
Informations sur les risques :
Groupe d'emballage :
LQ :

Question d’ordre technique sur : 3D-PP42137 H-SLFRAVITK^-OH

Veuillez plutôt utiliser le panier afin de demander un devis ou passer commande

Si vous souhaitez demander un devis ou passer commande, veuillez plutôt ajouter les produits souhaités à votre panier, puis demander un devis ou passer commande à partir de votre panier. C'est une méthode plus rapide, plus économique, et vous pourrez bénéficier des remises disponibles ainsi que d'autres avantages

* Champ obligatoire
Bienvenue chez CymitQuimica !Nous utilisons des cookies pour améliorer votre visite. Nous n’incluons pas de publicité.

Veuillez consulter notre Politique de Cookies pour plus de détails ou ajustez vos préférences dans "Configurer".